Etoricoxib

From Wikipedia, the free encyclopedia

You have new messages (last change).

Etoricoxib (brand name Tauxib® in Italy; Arcoxia®) is a new COX-2 selective inhibitor from Merck & Co. Doses are 60 to 120 mg/day. The Food and Drug Administration (FDA) is requiring additional safety and efficacy data for etoricoxib before it will issue approval. It has been registered in some European countries, e.g. the United Kingdom. It is also available and promoted in India, along with celecoxib. It is for the treatment of rheumatoid arthritis, osteoarthritis, chronic low back pain, gout, and ankylosing spondylitis.

[edit] External links


Non-steroidal anti-inflammatory drugs (primarily M01A and M02A, also N02BA) edit

Salicylates: Aspirin (Acetylsalicylic Acid), Diflunisal, Ethenzamide -- Arylalkanoic acids: Diclofenac, Indometacin, Sulindac

2-Arylpropionic acids (profens): Carprofen, Flurbiprofen, Ibuprofen, Ketoprofen, Ketorolac, Loxoprofen, Naproxen, Tiaprofenic acid,

N-Arylanthranilic acids (fenamic acids): Mefenamic acid -- Pyrazolidine derivatives: Phenylbutazone

Oxicams: Meloxicam, Piroxicam -- Coxibs: Celecoxib, Etoricoxib, Parecoxib, Rofecoxib, Valdecoxib -- Sulphonanilides: Nimesulide

Topically used products: Diclofenac, Flurbiprofen, Ibuprofen, Indometacin, Ketoprofen, Naproxen, Piroxicam


Pills  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org../../../e/t/o/Etoricoxib.html"
In other languages